SEC levies no fine against Kiromic BioPharma after material omissions self-disclosure
By 
Aaron Nicodemus2024-12-03T17:48:00
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission (SEC) after self-reporting that it failed to disclose material information about two cancer drugs to investors.
Houston-based Kiromic raised $40 million in a July 2021 public offering to fund clinical trials for two cancer drugs, but failed to alert investors that the U.S. Food and Drug Administration (FDA) had placed holds on clinical trials two weeks before the offering, the SEC said Tuesday in a press release. The company failed to report the FDA holds in two SEC filings, and failed to correct statements made by executives in roadshow calls with investors, according to the agency.
The allegations came to light after two anonymous complaints were filed on the company’s whistleblower hotline in August 2021, the SEC said.
Related articles
-
WebcastWebcast: The DOJ’s Corporate Whistleblower Program: What we’ve learned and how it can change in the future
We will discuss the critical role whistleblowers play in law enforcement, and how the DOJ has structured its program to incentivize people to come forward.
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
More from Regulatory Enforcement
-
ArticleFormer Capula CCO alleges misconduct and retaliation at the hedge fund firm
The former U.S. chief compliance officer of hedge fund firm Capula Investment Management has blown the whistle against his former employer, alleging he was terminated for raising concerns about improper expensing practices.
-
ArticleFINRA fines First Trust $10M for allegedly giving too-generous gifts to brokers
First Trust Portfolios has been fined $10 million by FINRA for allegedly providing excessive meals, gifts, and other incentives to broker-dealers.
-
ArticleCompliance officers accused of helping criminals run $346 million international payment fraud network
Four U.S. citizens were arrested in California Wednesday in connection with a massive, $346 million international credit card fraud scheme based in Germany, in which compliance officers were allegedly complicit, according to the DOJ.